The price of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares last traded on Wall Street rose 3.17% to $8.80.
Based on available information, 8 analysts follow Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $9.00, we find $12.50. Given the previous closing price of $8.53, this indicates a potential upside of 46.54 percent. RXRX stock price is now -14.59% away from the 50-day moving average and 4.12% away from the 200-day moving average. The market capitalization of the company currently stands at $1.87B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 5 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $15.13 as their price target over the next twelve months.
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc. (NASDAQ: RXRX).
In other news, Larson Tina Marriott, President and COO sold 3,000 shares of the company’s stock on Aug 24. The stock was sold for $25,968 at an average price of $8.66. Upon completion of the transaction, the President and COO now directly owns 418,782 shares in the company, valued at $3.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 22, Director Borgeson Blake sold 8,885 shares of the business’s stock. A total of $79,181 was realized by selling the stock at an average price of $8.91. This leaves the insider owning 7,460,730 shares of the company worth $65.65 million. Insiders disposed of 984,395 shares of company stock worth roughly $8.66 million over the past 1 year. A total of 5.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RXRX stock. A new stake in Recursion Pharmaceuticals Inc. shares was purchased by YONG RONG (HK) ASSET MANAGEMENT LTD during the first quarter worth $10,333,000. LINGOTTO INVESTMENT MANAGEMENT LLP invested $6,821,000 in shares of RXRX during the first quarter. In the first quarter, ENSIGN PEAK ADVISORS, INC acquired a new stake in Recursion Pharmaceuticals Inc. valued at approximately $1,489,000. ADVISORY RESEARCH INC acquired a new stake in RXRX for approximately $1,194,000. DIAMETRIC CAPITAL, LP purchased a new stake in RXRX valued at around $1,055,000 in the second quarter. In total, there are 235 active investors with 68.70% ownership of the company’s stock.
During the past 12 months, Recursion Pharmaceuticals Inc. has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.80, and a quick ratio of 3.80. The fifty day moving average price for RXRX is $10.30 and a two-hundred day moving average price translates $8.44 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.37 by -0.01. This compares to -$0.38 EPS in the same period last year. The company reported revenue of $11.02 million for the quarter, compared to $7.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.56 percent. For the current quarter, analysts expect RXRX to generate $13.22M in revenue.
Recursion Pharmaceuticals Inc.(RXRX) Company Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
